North America Oligonucleotide Therapeutics Market Size & Outlook
The oligonucleotide therapeutics market in North America is expected to reach a projected revenue of US$ 12,314.1 million by 2033. A compound annual growth rate of 17.3% is expected of North America oligonucleotide therapeutics market from 2026 to 2033.
Revenue, 2025 (US$M)
$3,424.7
Estimate, 2026 (US$M)
$4,020.6
Forecast, 2033 (US$M)
$12,314.1
CAGR, 2026 - 2033
17.3%
Global Market
Related Markets
North America oligonucleotide therapeutics market highlights
- The North America oligonucleotide therapeutics market generated a revenue of USD 3,424.7 million in 2025.
- The market is expected to grow at a CAGR of 17.3% from 2026 to 2033.
- In terms of segment, antisense oligonucleotides (asos) was the largest revenue generating oligonucleotide class in 2025.
- MicroRNA (miRNA) is the most lucrative oligonucleotide class segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 3,424.7 million |
| Market revenue in 2033 | USD 12,314.1 million |
| Growth rate | 17.3% (CAGR from 2026 to 2033) |
| Largest segment | Antisense oligonucleotides (asos) |
| Fastest growing segment | MicroRNA (miRNA) |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Aptamers, MicroRNA (miRNA), CpG Oligonucleotides, Other Oligonucleotide Therapeutics |
Other key industry trends
- In terms of revenue, North America region accounted for 47.6% of the global oligonucleotide therapeutics market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,914.3 million by 2033.
No credit card required*
Publish Date: May 25, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Oligonucleotide Therapeutics Market Scope
Oligonucleotide Therapeutics Market segmentation & scope
Oligonucleotide Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Nitto Denko Corp | View profile | 28,193 | 4-20, Ofuka-Cho, 33rd Floor, Grand Front Osaka, Kita-Ku, Osaka, Japan, 530-0011 | www.nitto.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
| Biogen Inc | View profile | 7,570 | 225 Binney Street, Cambridge, MA, United States, 02142 | www.biogen.com |
| Ionis Pharmaceuticals Inc | View profile | 927 | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 | www.ionispharma.com |
| Alnylam Pharmaceuticals Inc | View profile | 2,100 | 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, United States, 02142 | www.alnylam.com |
| Arrowhead Pharmaceuticals Inc | View profile | 525 | 177 E. Colorado Boulevard, Suite 700, Pasadena, CA, United States, 91105 | www.arrowheadpharma.com |
| Silence Therapeutics PLC | View profile | 109 | 72 Hammersmith Road, London, United Kingdom, W14 8TH | www.silence-therapeutics.com |
| Sarepta Therapeutics Inc | View profile | 1,314 | 215 First Street, Suite 415, Cambridge, MA, United States, 02142 | www.sarepta.com |
| Wave Life Sciences | View profile | 251-500 | Boston, Massachusetts, United States, North America | wavelifesciences.com |
North America Oligonucleotide Therapeutics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Oligonucleotide Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Antisense Oligonucleotides (Asos) was the largest segment with a revenue share of 53.62% in 2025.
Horizon Databook has segmented the North America oligonucleotide therapeutics market based on antisense oligonucleotides (asos), small interfering rna (sirna), aptamers, microrna (mirna), cpg oligonucleotides, other oligonucleotide therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.
- North America Oligonucleotide Therapeutics Market Oligonucleotide Class Outlook (Revenue, USD Million , 2021-2033)
- Antisense Oligonucleotides (ASOs)
- Small Interfering RNA (siRNA)
- Aptamers
- microRNA (miRNA)
- CpG Oligonucleotides
- Other Oligonucleotide Therapeutics
- North America Oligonucleotide Therapeutics Market Therapeutic Area Outlook (Revenue, USD Million , 2021-2033)
- Neurology
- Oncology
- Cardiometabolic Disorders
- Infectious Diseases
- Ophthalmology
- Other Therapeutic Areas
- North America Oligonucleotide Therapeutics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Subcutaneous
- Intravenous
- Intrathecal
- Intramuscular
- Other Routes
Reasons to subscribe to Oligonucleotide Therapeutics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Oligonucleotide Therapeutics Market Outlook databook
- Our clientele includes a mix of Oligonucleotide Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Oligonucleotide Therapeutics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Oligonucleotide Therapeutics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Oligonucleotide Therapeutics Market, 2021-2033 (US$M)
North America oligonucleotide therapeutics market statistics, by oligonucleotide class, 2021-2033 (US$M)
